Dental Growth Factor Extracts Panel Go-Ahead; Sankyo To Market GEM 21S

BioMimetic Pharmaceuticals' GEM 21S synthetic bone-growth factor should be approved to treat osseous defects that result from periodontal disease, but not from other causes, FDA's Dental Products Panel recommended in Gaithersburg, Md. July 13